Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy DisorderAccesswire · 4 days ago
Jaguar Health Provides Update Regarding Special Stock DividendAccesswire · Oct 14, 2026
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's CrofelemerAccesswire · Oct 14, 2026
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendAccesswire · Oct 13, 2026
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu DhabiAccesswire · Oct 6, 2026
Jaguar Health Announces a Special Stock DividendAccesswire · Oct 2, 2026Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 19, 2026 | -$565.81 | -$235.38 | Beat |
| May 20, 2026 | -$10.71 | -$2.04 | Beat |
| Apr 7, 2026 | -$1.49 | -$3.14 | Miss |
| Nov 12, 2025 | -$1.78 | -$2.20 | Miss |
| Aug 14, 2025 | -$2.50 | -$3.59 | Miss |
| May 15, 2025 | -$3.79 | -$5.85 | Miss |